Sagimet Biosciences Inc. Series A (SGMT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SGMT SEC filings page.
This page shows Sagimet Biosciences Inc. Series A (SGMT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The reported figures describe a development-stage biotech funded mainly by equity, with research spending and cash outflows still rising.
From FY2023 to FY2025, R&D spending nearly doubled from$19.8M to$39.1M , while operating cash outflow widened from$23.8M to$45.7M . That pairing indicates the larger investment program has not yet produced operating self-funding in the reported periods.
In FY2023, R&D was
In FY2025, liabilities were only
Financial Health Signals
Sagimet Biosciences Inc. Series A does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Sagimet Biosciences Inc. Series A passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Sagimet Biosciences Inc. Series A reported a net loss of $51.0M while operations used $45.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Sagimet Biosciences Inc. Series A reported -$14.0M in net income in Q2 2026. This represents a decrease of 34.3% from the same quarter a year earlier. Against the prior quarter it is down 31.0%.
Sagimet Biosciences Inc. Series A earned -$0.26 per diluted share (EPS) in Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Sagimet Biosciences Inc. Series A held $165.9M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Sagimet Biosciences Inc. Series A's ROE was -5.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 2.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.9 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Sagimet Biosciences Inc. Series A invested $11.5M in research and development in Q2 2026. This represents an increase of 59.1% from the same quarter a year earlier. Against the prior quarter it is up 64.9%.
Not reported for Q2 2026.
Not reported for Q2 2026.
SGMT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $11.5M+59.1% | $7.0M-54.4% | N/A | $9.7M-23.1% | $7.2M+14.8% | $15.3M+191.6% | N/A | $12.7M+155.2% |
| SG&A Expenses | $4.3M-8.4% | $4.7M+4.3% | N/A | $4.6M+8.4% | $4.7M+9.4% | $4.5M+29.0% | N/A | $4.2M-5.5% |
| Operating Income | -$15.8M-32.6% | -$11.7M+41.0% | N/A | -$14.3M+15.2% | -$11.9M-12.6% | -$19.9M-126.6% | N/A | -$16.9M-126.8% |
| Net Income | -$14.0M-34.3% | -$10.7M+41.4% | N/A | -$12.9M+11.7% | -$10.4M-27.9% | -$18.2M-174.2% | N/A | -$14.6M-130.1% |
| EPS (Basic) | -$0.26+18.8% | -$0.33+41.1% | -$0.30+40.0% | -$0.40+11.1% | -$0.32-28.0% | -$0.56-143.5% | -$0.50-189.3% | -$0.45-28.6% |
| EPS (Diluted) | -$0.26 | -$0.33+41.1% | -$0.30+40.0% | -$0.40+11.1% | -$0.32-28.0% | -$0.56-143.5% | -$0.50-189.3% | -$0.45 |
| Diluted Shares (Avg) | 53M | 33M+1.1% | N/A | 32M+1.0% | 32M+0.9% | 32M+10.9% | N/A | 32M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Interest Expense, Income Tax.
SGMT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $263.4M+91.7% | $107.8M-26.3% | $116.5M-27.3% | $128.4M-26.5% | $137.4M-27.3% | $146.2M-24.9% | $160.3M+65.7% | $174.8M+69.8% |
| Current Assets | $244.0M+91.8% | $107.7M-26.3% | $116.4M-23.8% | $119.5M-24.0% | $127.2M-23.7% | $146.1M-24.9% | $152.8M+58.1% | $157.2M+52.9% |
| Cash & Equivalents | $165.9M+291.9% | $36.6M-43.4% | $35.0M-53.8% | $32.5M-57.8% | $42.3M-55.9% | $64.7M-63.4% | $75.8M+0.9% | $77.0M-24.4% |
| Short-Term Investments | $74.2M-10.6% | $67.9M-15.0% | $78.1M+3.6% | $84.2M+11.6% | $83.1M+18.0% | $79.9M+371.7% | $75.4M+281.7% | $75.5M |
| Long-Term Investments | $17.4M+73.3% | $0 | $0-100.0% | $8.8M-49.6% | $10.1M-54.5% | $0 | $7.4M | $17.5M |
| Total Liabilities | $7.3M+0.4% | $5.3M-26.2% | $5.1M+14.5% | $9.1M+123.5% | $7.2M+26.5% | $7.2M+59.2% | $4.5M-21.2% | $4.1M-19.0% |
| Current Liabilities | $5.4M-25.2% | $5.3M | $5.1M+14.5% | $9.1M | $7.2M | N/A | $4.5M-21.2% | N/A |
| Non-Current Liabilities | $1.9M | $0 | $0 | $0 | $0 | N/A | $0 | N/A |
| Total Equity | $256.2M+96.8% | $102.5M-26.3% | $111.4M-28.5% | $119.3M-30.1% | $130.2M-29.0% | $139.0M-26.9% | $155.8M+71.1% | $170.7M+74.4% |
| Retained Earnings | -$371.0M-14.5% | -$357.0M-13.9% | -$346.3M-17.3% | -$336.8M-20.7% | -$323.9M-22.5% | -$313.5M-22.3% | -$295.3M-18.2% | -$279.1M-15.5% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
SGMT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.1M-22.0% | -$8.6M+40.8% | -$11.8M-7.3% | -$10.2M+48.0% | -$9.1M-61.5% | -$14.5M-134.1% | -$11.0M-55.6% | -$19.6M-404.5% |
| Stock-Based Compensation | $3.7M+131.0% | $1.8M+24.9% | N/A | $1.7M+9.2% | $1.6M+10.3% | $1.5M+93.9% | N/A | $1.5M-16.7% |
| Investing Cash Flow | -$24.0M-80.7% | $10.2M+199.3% | $14.4M+45.8% | $75K-88.0% | -$13.3M+82.3% | $3.4M+13.8% | $9.8M+150.2% | $624K |
| Financing Cash Flow | N/A | N/A | $0 | $274K | N/A | N/A | $0 | $0-100.0% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
SGMT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -5.5%+2.5pp | -10.4%+2.7pp | N/A | -10.8%-2.3pp | -8.0%-3.5pp | -13.1%-9.6pp | N/A | -8.6%-2.1pp |
| Return on Assets | -5.3%+2.3pp | -9.9%+2.5pp | N/A | -10.1%-1.7pp | -7.6%-3.3pp | -12.4%-9.0pp | N/A | -8.4%-2.2pp |
| Current Ratio | 45.02+27.5x | 20.34 | 22.82-11.5x | 13.06 | 17.55 | N/A | 34.30+17.2x | N/A |
| Debt-to-Equity | 0.030.0x | 0.050.0x | 0.050.0x | 0.08+0.1x | 0.060.0x | 0.050.0x | 0.030.0x | 0.020.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Sagimet Biosciences Inc. Series A SGMT | FY2025 | N/A | -$51.0M | N/A | $633.2M | — |
| Silence Therapeutics Plc SLN | FY2025 | $559K | -$88.6M | N/A | $612.8M | — |
| Neumora Therapeutics, Inc. NMRA | FY2025 | N/A | $236.9M | N/A | $90.2M | — |
Where Sagimet Biosciences Inc. Series A Ranks
Frequently Asked Questions
Is Sagimet Biosciences Inc. Series A profitable?
No, Sagimet Biosciences Inc. Series A (SGMT) reported a net income of -$51.0M in fiscal year 2025.
What is Sagimet Biosciences Inc. Series A's return on equity (ROE)?
Sagimet Biosciences Inc. Series A (SGMT) has a return on equity of -45.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Sagimet Biosciences Inc. Series A's operating cash flow?
Sagimet Biosciences Inc. Series A (SGMT) recorded an outflow of $45.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Sagimet Biosciences Inc. Series A's total assets?
Sagimet Biosciences Inc. Series A (SGMT) had $116.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Sagimet Biosciences Inc. Series A spend on research and development?
Sagimet Biosciences Inc. Series A (SGMT) invested $39.1M in research and development during fiscal year 2025.
What is Sagimet Biosciences Inc. Series A's current ratio?
Sagimet Biosciences Inc. Series A (SGMT) had a current ratio of 22.82 as of fiscal year 2025, which is generally considered healthy.
What is Sagimet Biosciences Inc. Series A's debt-to-equity ratio?
Sagimet Biosciences Inc. Series A (SGMT) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sagimet Biosciences Inc. Series A's return on assets (ROA)?
Sagimet Biosciences Inc. Series A (SGMT) had a return on assets of -43.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Sagimet Biosciences Inc. Series A's P/E ratio?
Sagimet Biosciences Inc. Series A (SGMT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $633.2M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Sagimet Biosciences Inc. Series A's price-to-sales ratio?
Sagimet Biosciences Inc. Series A (SGMT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $633.2M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Sagimet Biosciences Inc. Series A's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Sagimet Biosciences Inc. Series A (SGMT) held $113.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $45.6M over that year. Dividing the one by the other, the reported balance equals about 30 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Sagimet Biosciences Inc. Series A's Piotroski F-Score?
Sagimet Biosciences Inc. Series A (SGMT) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sagimet Biosciences Inc. Series A's earnings high quality?
Sagimet Biosciences Inc. Series A (SGMT) reported a net loss of $51.0M while operations used $45.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.